| Dr Mark J Whalen, MD | |
|
2525 Court Dr, Gastonia, NC 28054-2140 | |
| (704) 834-2851 | |
| (704) 834-2815 |
| Full Name | Dr Mark J Whalen |
|---|---|
| Gender | Male |
| Speciality | Pathology |
| Experience | 34 Years |
| Location | 2525 Court Dr, Gastonia, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1891795498 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 95-01148 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Caromont Regional Medical Center | Gastonia, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Caromont Medical Group Inc | 3577476258 | 328 |
News Archive
Pharma Two B announced today it is planning a Phase II study of its new combination therapy, P2B001, in development as a treatment for the early stages of Parkinson's disease. Assuming regulatory approval and the necessary financing, the company plans to commence the Phase II trial in Q4 2011.
Every day nearly 200 people die from an overdose of drugs or from alcohol poisoning, with opioids responsible for the majority.
Male high school athletes' ability to recognize and intervene to stop dating violence - the physical, sexual and emotional aggression prevalent in adolescent romantic relationships - is improved with the intervention of some of the most important role models in young men's lives: their coaches.
CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Corifact™, Factor XIII Concentrate (Human), for the routine prophylactic treatment of congenital factor XIII (FXIII) deficiency. Corifact, already available for use in 12 countries throughout the world under the trade name Fibrogammin®- P, is the first and only FXIII concentrate approved in the U.S.
› Verified 7 days ago
| Entity Name | Caromont Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356314272 PECOS PAC ID: 3577476258 Enrollment ID: O20031201000070 |
News Archive
Pharma Two B announced today it is planning a Phase II study of its new combination therapy, P2B001, in development as a treatment for the early stages of Parkinson's disease. Assuming regulatory approval and the necessary financing, the company plans to commence the Phase II trial in Q4 2011.
Every day nearly 200 people die from an overdose of drugs or from alcohol poisoning, with opioids responsible for the majority.
Male high school athletes' ability to recognize and intervene to stop dating violence - the physical, sexual and emotional aggression prevalent in adolescent romantic relationships - is improved with the intervention of some of the most important role models in young men's lives: their coaches.
CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Corifact™, Factor XIII Concentrate (Human), for the routine prophylactic treatment of congenital factor XIII (FXIII) deficiency. Corifact, already available for use in 12 countries throughout the world under the trade name Fibrogammin®- P, is the first and only FXIII concentrate approved in the U.S.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mark J Whalen, MD 4007 Wild Nursery Ct, Charlotte, NC 28215-5345 Ph: (704) 616-7387 | Dr Mark J Whalen, MD 2525 Court Dr, Gastonia, NC 28054-2140 Ph: (704) 834-2851 |
News Archive
Pharma Two B announced today it is planning a Phase II study of its new combination therapy, P2B001, in development as a treatment for the early stages of Parkinson's disease. Assuming regulatory approval and the necessary financing, the company plans to commence the Phase II trial in Q4 2011.
Every day nearly 200 people die from an overdose of drugs or from alcohol poisoning, with opioids responsible for the majority.
Male high school athletes' ability to recognize and intervene to stop dating violence - the physical, sexual and emotional aggression prevalent in adolescent romantic relationships - is improved with the intervention of some of the most important role models in young men's lives: their coaches.
CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Corifact™, Factor XIII Concentrate (Human), for the routine prophylactic treatment of congenital factor XIII (FXIII) deficiency. Corifact, already available for use in 12 countries throughout the world under the trade name Fibrogammin®- P, is the first and only FXIII concentrate approved in the U.S.
› Verified 7 days ago
Dr. David R Guillen, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 1072 X Ray Dr, Gastonia, NC 28054 Phone: 704-671-1094 | |
Chris Brian Nguyen, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 2525 Court Dr, Department Of Pathology, Gaston Memorial Hospital, Gastonia, NC 28054 Phone: 704-915-9579 | |
Dr. Peter H Wittenberg, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 2525 Court Dr, Gastonia, NC 28054 Phone: 704-834-2851 Fax: 704-834-2815 | |
Mara Banks, MD, PHD Pathology Medicare: Accepting Medicare Assignments Practice Location: 2525 Court Dr, Gastonia, NC 28054 Phone: 704-834-2450 Fax: 704-671-5331 | |
Dr. Cheryl Levine, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 1740 Montclair Ave, Gastonia, NC 28054 Phone: 704-865-2464 | |
Jeffrey Todd Bunning, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 2555 Court Dr Ste 270, Gastonia, NC 28054 Phone: 704-671-5313 | |
Jeffrey Ahlstedt, Pathology Medicare: Accepting Medicare Assignments Practice Location: 2525 Court Dr, Gastonia, NC 28054 Phone: 704-834-2851 |